Jiangsu HengRui Medicine Co.Ltd.
SOX Chemotherapy(Jiangsu HengRui Medicine Co., Ltd.)은 Gastric Cancer (GC) 표적 치료제로, Gastric Cancer (GC); Gastroesophageal Junction Cancer 영역에서 개발·상용화 중입니다. 작용기전: by which THSD4 affects GCPM and validate its clinical utility as a predictive biomarker for IP PTX response. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 60건의 관련 임상이 등록되어 있습니다. 차별점: Novel Nutrition-Based Nomogram to Predict Severe Neutropenia After Adjuvant Chemotherapy in Gastric Cancer.
Gastric Cancer (GC)
Gastric Cancer (GC); Gastroesophageal Junction Cancer
Recruiting
Deruxtecan]
lipid nanoparticles (SLN) and ketorolac (KT) incorporated into a hydrogel matrix (DC-SLN gel) for
Novel Nutrition-Based Nomogram to Predict Severe Neutropenia After Adjuvant Chemotherapy in Gastric Cancer
by which THSD4 affects GCPM and validate its clinical utility as a predictive biomarker for IP PTX response
T cells, suggesting dynamic remodeling from broad systemic activation
apoptosis, sphere formation to assess stemness, and Western blot for SOX-2, OCT-4, Bax, and Bcl2 expression
PD-L1 combined positive
resistance to doxorubicin and cisplatin (↑IC50), inhibited apoptosis, and enhanced stemness via upregulation of SOX-2 and OCT-
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Jiangsu HengRui Medicine Co.Ltd.
SOX Chemotherapy(Jiangsu HengRui Medicine Co., Ltd.)은 Gastric Cancer (GC) 표적 치료제로, Gastric Cancer (GC); Gastroesophageal Junction Cancer 영역에서 개발·상용화 중입니다. 작용기전: by which THSD4 affects GCPM and validate its clinical utility as a predictive biomarker for IP PTX response. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 60건의 관련 임상이 등록되어 있습니다. 차별점: Novel Nutrition-Based Nomogram to Predict Severe Neutropenia After Adjuvant Chemotherapy in Gastric Cancer.
Gastric Cancer (GC)
Gastric Cancer (GC); Gastroesophageal Junction Cancer
Recruiting
Deruxtecan]
lipid nanoparticles (SLN) and ketorolac (KT) incorporated into a hydrogel matrix (DC-SLN gel) for
Novel Nutrition-Based Nomogram to Predict Severe Neutropenia After Adjuvant Chemotherapy in Gastric Cancer
by which THSD4 affects GCPM and validate its clinical utility as a predictive biomarker for IP PTX response
T cells, suggesting dynamic remodeling from broad systemic activation
apoptosis, sphere formation to assess stemness, and Western blot for SOX-2, OCT-4, Bax, and Bcl2 expression
PD-L1 combined positive
resistance to doxorubicin and cisplatin (↑IC50), inhibited apoptosis, and enhanced stemness via upregulation of SOX-2 and OCT-
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.